Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conditioning Regimen and T-cell Depleted HSCT for Fanconi Anemia
NCT00630253Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Feb 2000
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, fludarabine, antithymocyte globulin rabbit in Fanconi anemia (FA), sponsored by Masonic Cancer Center. Started Feb 2000; status: completed.
02
Drugs
cyclophosphamidefludarabineantithymocyte globulin rabbit
03
Conditions
Fanconi anemia (FA)
Beyond the preview
Go deeper on NCT00630253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00630253.